当前位置: 首页 >> 检索结果
390. Mapping the global prevalence, incidence, and mortality of Plasmodium falciparum and Plasmodium vivax malaria, 2000-22: a spatial and temporal modelling study.
作者: Daniel J Weiss.;Paulina A Dzianach.;Adam Saddler.;Jailos Lubinda.;Annie Browne.;Michael McPhail.;Susan F Rumisha.;Francesca Sanna.;Yalemzewod Gelaw.;Juniper B Kiss.;Sarah Hafsia.;Rubini Jayaseelen.;Hunter S Baggen.;Punam Amratia.;Amelia Bertozzi-Villa.;Olivia Nesbit.;Joanna Whisnant.;Katherine E Battle.;Michele Nguyen.;Kefyalew Addis Alene.;Ewan Cameron.;Melissa A Penny.;Samir Bhatt.;David L Smith.;Tasmin L Symons.;Jonathan F Mosser.;Christopher J L Murray.;Simon I Hay.;Peter W Gething.
来源: Lancet. 2025年405卷10483期979-990页
Malaria remains a leading cause of illness and death globally, with countries in sub-Saharan Africa bearing a disproportionate burden. Global high-resolution maps of malaria prevalence, incidence, and mortality are crucial for tracking spatially heterogeneous progress against the disease and to inform strategic malaria control efforts. We present the latest such maps, the first since 2019, which cover the years 2000-22. The maps are accompanied by administrative-level summaries and include estimated COVID-19 pandemic-related impacts on malaria burden.
393. Atosiban versus placebo for threatened preterm birth (APOSTEL 8): a multicentre, randomised controlled trial.
作者: Larissa I van der Windt.;Job Klumper.;Ruben G Duijnhoven.;Marjolein Kok.;Carrie Ris-Stalpers.;Marjon A de Boer.;Anton H van Kaam.;Eva Pajkrt.;Ben W Mol.;Kate F Walker.;Fionnuala M McAuliffe.;Joris A van der Post.;Carolien Roos.;Martijn A Oudijk.; .
来源: Lancet. 2025年405卷10483期1004-1013页
Tocolytics are recommended in international guidelines as treatment for threatened preterm birth. Atosiban, an oxytocin receptor antagonist, is a registered tocolytic drug specifically indicated for the treatment of threatened preterm birth. Although tocolytics have been shown to delay birth, benefits on neonatal outcomes have not been demonstrated. In the APOSTEL 8 trial we aimed to assess superiority of tocolysis with atosiban compared with placebo in threatened preterm birth from 30 weeks and 0 days (30+0 weeks) to 33+6 weeks of gestation in improving neonatal morbidity and mortality.
394. Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021.
Overweight and obesity is a global epidemic. Forecasting future trajectories of the epidemic is crucial for providing an evidence base for policy change. In this study, we examine the historical trends of the global, regional, and national prevalence of adult overweight and obesity from 1990 to 2021 and forecast the future trajectories to 2050.
395. Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021.
Despite the well documented consequences of obesity during childhood and adolescence and future risks of excess body mass on non-communicable diseases in adulthood, coordinated global action on excess body mass in early life is still insufficient. Inconsistent measurement and reporting are a barrier to specific targets, resource allocation, and interventions. In this Article we report current estimates of overweight and obesity across childhood and adolescence, progress over time, and forecasts to inform specific actions.
398. Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials.
作者: Philippe Gevaert.;Martin Desrosiers.;Marjolein Cornet.;Joaquim Mullol.;Eugenio De Corso.;Nesil Keles Turel.;Jorge Maspero.;Shigeharu Fujieda.;Luo Zhang.;Ana R Sousa.;Samantha J Woods.;Angela M Davis.;Stein Schalkwijk.;Dawn Edwards.;Prerna Ranganathan.;Richard Follows.;Carolynne Marshall.;Joseph K Han.; .
来源: Lancet. 2025年405卷10482期911-926页
Chronic rhinosinusitis with nasal polyps (CRSwNP) symptoms are frequently driven by type 2 inflammation. Depemokimab is the first ultra-long-acting biological drug engineered with enhanced interleukin-5 binding affinity, high potency, and an extended half-life, enabling twice per year dosing and sustained type 2 inflammation inhibition. The ANCHOR-1 and ANCHOR-2 trials investigated the efficacy and safety of depemokimab in people with CRSwNP.
399. Rebuilding trust and equity in Syria's health system: a governance-driven transition.
作者: Munzer Alkhalil.;Aula Abbara.;Mayssoon Dashash.;Richard Sullivan.;Maher Aboumayaleh.;Abdulkarim Ekzayez.;Zuhair Kharrat.;Reem Hasan Obaydo.;Zeidoun Alzoubi.;Majd Alghatrif.;Fouad M Fouad.
来源: Lancet. 2025年405卷10482期876-878页 |